Brief: Hansa Biopharma Says Phase 3 Trial Did Not Meet Primary Endpoint
16/12/2025 22:08
Dec 16 (Reuters) - Hansa Biopharma AB HNSA.ST: HANSA BIOPHARMA AB - PHASE 3 TRIAL DID NOT MEET PRIMARY ENDPOINT HANSA PROVIDES UPDATE ON PIVOTAL PHASE 3 TRIAL IN ANTI-GLOMERULAR BASEMENT MEMBRANE (ANTI-GBM) DISEASE Source text: ID:nWkrSD59v Further company coverage: HNSA.ST ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS